Ibrance Generics Arrive In India, Patient Programs Add Free Drug Component
Executive Summary
Pfizer’s Ibrance is set to lose exclusivity in the US only by 2027, but the Indian market is buzzing with activity as generics including from top-ranked drug maker Sun Pharma vie for a share of the pie. Competing CDK4/6 inhibitors are already available but can cut-price palbociclib versions alter market dynamics?
You may also be interested in...
Pfizer Ibrance India Case: ‘Willful Contempt’ Lands Local Firm In Soup
An Indian court has directed a local firm to pay a specified sum to Pfizer for contempt of court in a case pertaining to its patent on palbociclib, failing which its senior executive could face a two-week prison term.
Deals, Divestitures In Store As Dr Reddy’s Stays Course To Top Five India League
Investments in differentiated and specialty products and collaborations, alongside divestitures, are part of Dr Reddy’s plans as it seeks to move up the rankings in India. Momentum in China, including an alliance with Sunflower Pharma for orphan diseases, is also being keenly watched.
Deals, Divestitures In Store As Dr Reddy’s Stays Course To Top 5 India League
Investments in differentiated and specialty products and collaborations, alongside divestitures, are part of Dr Reddy’s plans as it seeks to move up the rankings in India. Momentum in China, including an alliance with Sunflower Pharma for orphan diseases, is also being keenly watched.